Connect with us


Affinor Growers Inc. (OTCMKTS: RSSFF) Strengthens Its Advisory Board, AXIM Biotechnologies Inc. (OTCMKTS: AXIM) Makes Medical Advisory Board Appointment



Affinor Growers Inc. (OTCMKTS: RSSFF) has appointed Ben Hogervorst to its Advisory Board to help it in business execution and its five-year growth strategy domestically and internationally.

Beh Hogervorst joins Affinor Growers’ advisory board 

Hogervorst is the CEO and co-founder of Britespan Building Systems Inc. and has been in the fabric business for more than 25 years.  Under his leadership, Britespan has seen rapid growth since its establishment in 2010 to become an industry leader on innovative building solutions offering.

Affinor CEO Nick Brusatore stated, “Having Mr. Hogervorst on our advisory team adds building structure manufacturing experience and further design capabilities to Affinor. The possibilities for innovation in agriculture are endless and extremely exciting from a design standpoint. I expect that this relationship will add considerable value to Affinor’s scaleup plans.”

The company has also announced the issuance of 5 million stock options to two company consultants to acquire 5 million shares of its common stock as per Affinor’s stock option plan. Around 4 million options will vest immediately and will be exercisable at $0.03 per share, and the remaining 1 million options will vest over the course of the ten-year term and are exercisable at $0.05 per share.

AXIM Biotechnologies appoint Michael Stern To Medical Advisory Board 

AXIM Biotechnologies Inc. (OTCMKTS: AXIM) has appointed Michael E. Stern to its Medical Advisory Board. Stern joins four other Advisory Board Members, including Chairman Joseph Tauber, Henry Perry, Laura Periman, and Kelly Nichols.

CEO John W. Huemoeller II said, “Our Medical Advisory Board just keeps getting better. Michael is a highly regarded scientific professional in Dry Eye Disease as well as OSD. His three decades of experience leading laboratory research for big and small companies, combined with his extensive academic experience and connections will serve Axim well as we prepare to commercialize our two FDA-approved DED diagnostic tests.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.